---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-019858"
form_type: "8-K"
ticker: "TRVI"
cik: "0001563880"
company_name: "Trevi Therapeutics, Inc."
filed_at: "2022-05-12T23:59:59+00:00"
generated_at: "2026-06-25T18:20:15.769383+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Trevi Q1 net loss $7.3M; Phase 2 CANAL shows 52% placebo-adjusted cough reduction; $55M financing closed

## Summary
- Q1 2022 net loss $7.3M vs $8.4M prior year; R&D expenses $4.6M down from $5.6M.
- Cash $29.1M at March 31; plus $55M gross from April private placement for Haduvio development.
- Phase 2 CANAL interim (N=26): 77.3% reduction daytime cough vs 25.7% placebo (p<0.0001); enrollment ended early.
- Full CANAL data expected Q3 2022; Phase 2b/3 PRISM (PN) top-line data expected Q2 2022.
- Phase 2b/3 PRISM enrollment completed Jan 2022; data readout anticipated in current quarter.

## SEC filing metadata
- accession: 0001564590-22-019858
- form_type: 8-K
- ticker: TRVI
- cik: 0001563880
- company_name: Trevi Therapeutics, Inc.
- filed_at: 2022-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1563880/000156459022019858/0001564590-22-019858-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1563880/000156459022019858/trvi-8k_20220512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-019858
- JSON: https://secwatch.observer/filing/0001564590-22-019858.json
- Plain text: https://secwatch.observer/filing/0001564590-22-019858.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.